Healthcare · Biotechnology
Price
$491.34
Market Cap
$124.7B
Employees
6,100
Beta
0.31
Avg Volume
1,283,126
CEO
Reshma Kewalramani
Business Description
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Business History
Price Overview
Last updated: Jun 27, 2026 8:58am (just now)$491.34
+11.16 (+2.32%)
Day Range
$482.20 – $503.89
52-Week Range
$362.50 – $507.92
50-Day MA
$441.52
200-Day MA
$441.64
Volume
5,669,334.00
Analyst Price Targets
Low
$436.00
Consensus
$553.93
High
$616.00
(93 analysts)
Share Structure
Outstanding
253,805,417.00
Float
253,023,696.00
Free Float
99.7%
High free float
— 99.7% of shares trade freely, ~0.3% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
28.78
Stock Price: $491.34
EPS (Diluted): 15.46
EPS (Diluted): 15.46
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
6.21
Stock Price: $491.34
Total Equity: $18.67B
Shares: 258,000,000
Total Equity: $18.67B
Shares: 258,000,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
22.48
Market Cap: $124.70B
Total Debt: $1.93B
Cash: $5.09B
EBITDA: $4.86B
Total Debt: $1.93B
Cash: $5.09B
EBITDA: $4.86B
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$114.7B
Market Cap: $124.70B
Total Debt: $1.93B
Cash: $5.09B
Total Debt: $1.93B
Cash: $5.09B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
85.0%
Gross Profit: $10.27B
Revenue: $12.07B
Revenue: $12.07B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
39.4%
Operating Income: $4.76B
Revenue: $12.07B
Revenue: $12.07B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
32.7%
Net Income: $3.95B
Revenue: $12.07B
Revenue: $12.07B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
23.9%
Net Income: $3.95B
Total Equity: $18.67B
Total Equity: $18.67B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
17.7%
Operating Income: $4.76B
Tax Rate: 14.9%
Equity: $18.67B
Total Debt: $1.93B
Cash: $5.09B
Tax Rate: 14.9%
Equity: $18.67B
Total Debt: $1.93B
Cash: $5.09B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.90
Current Assets: $11.20B
Current Liabilities: $3.86B
Current Liabilities: $3.86B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.10
Short-Term Debt: $82.80M
Long-Term Debt: $1.85B
Total Debt: $1.93B
Total Equity: $18.67B
Long-Term Debt: $1.85B
Total Debt: $1.93B
Total Equity: $18.67B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$46.80
Revenue: $12.07B
Shares: 258,000,000
Shares: 258,000,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$72.35
Total Equity: $18.67B
Shares: 258,000,000
Shares: 258,000,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$12.38
Operating CF: $3.63B
CapEx: -$437.60M
Shares: 258,000,000
CapEx: -$437.60M
Shares: 258,000,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $491.34
Stock Price: $491.34
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $3.95B
Net Income: $3.95B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VRTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 3:02am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $7.6B | $8.9B | $9.9B | $11.0B | $12.1B |
| Cost of Revenue | $904.2M | $1.1B | $1.3B | $1.5B | $1.8B |
| Gross Profit | $6.7B | $7.9B | $8.6B | $9.5B | $10.3B |
| Operating Expenses | $3.9B | $3.5B | $4.8B | $9.7B | $5.5B |
| Operating Income | $2.8B | $4.3B | $3.8B | -$232.9M | $4.8B |
| Net Income | $2.3B | $3.3B | $3.6B | -$535.6M | $4.0B |
| EBITDA | $2.9B | $4.4B | $4.6B | $486.3M | $4.9B |
| EPS | $9.09 | $12.97 | $14.05 | $-2.08 | $15.46 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 3:02am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.8B | $10.5B | $10.4B | $4.6B | $5.1B |
| Total Current Assets | $9.6B | $13.2B | $14.1B | $9.6B | $11.2B |
| Total Assets | $13.4B | $18.2B | $22.7B | $22.5B | $26.1B |
| Current Liabilities | $2.1B | $2.7B | $3.5B | $3.6B | $3.9B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $1.8B |
| Total Liabilities | $3.3B | $4.2B | $5.1B | $6.1B | $7.5B |
| Total Equity | $10.1B | $13.9B | $17.6B | $16.4B | $18.7B |
| Retained Earnings | $3.2B | $6.5B | $10.1B | $9.6B | $13.6B |
Cash Flow (Annual)
Last updated: Jun 24, 2026 3:02am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.6B | $4.1B | $3.5B | -$492.6M | $3.6B |
| Capital Expenditure | -$235.0M | -$204.7M | -$258.4M | -$297.7M | -$437.6M |
| Free Cash Flow | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B |
| Acquisitions (net) | $77.0M | -$295.9M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.4B | -$172.0M | -$427.6M | -$1.2B | -$2.0B |
| Net Change in Cash | $811.2M | $3.7B | -$139.7M | -$5.8B | $515.6M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 5:27pm (15h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$14.3B $13.4B – $16.2B
|
$15.8B $15.8B – $15.8B
|
$17.6B $17.0B – $18.9B
|
$19.4B $18.7B – $20.8B
|
| EBITDA |
$5.1B $4.8B – $5.8B
|
$5.7B $5.7B – $5.7B
|
$6.3B $6.1B – $6.8B
|
$7.0B $6.7B – $7.5B
|
| Net Income |
$5.6B $5.1B – $6.1B
|
$6.0B $4.7B – $9.0B
|
$7.4B $7.1B – $8.1B
|
$8.5B $8.2B – $9.4B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 3:02am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +17.9% | +10.5% | +11.7% | +9.6% |
| Gross Profit Growth | +17.7% | +9.6% | +10.3% | +8.2% |
| Operating Income Growth | +54.8% | -11.0% | -106.1% | +2,144.1% |
| Net Income Growth | +41.8% | +9.0% | -114.8% | +838.1% |
| EBITDA Growth | +52.0% | +3.8% | -89.4% | +900.1% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Bozic Carmen | S-Sale | 1,020.00 | $462.17 | $471,413 |
| 2026-06-15 | Bozic Carmen | S-Sale | 4,062.00 | $450.00 | $1.8M |
| 2026-06-05 | Bozic Carmen | S-Sale | 1,745.00 | $450.00 | $785,250 |
| 2026-05-29 | Bozic Carmen | S-Sale | 1,974.00 | $450.00 | $888,300 |
| 2026-05-15 | Bunnage Mark E. | S-Sale | 33.00 | $453.45 | $14,964 |
| 2026-05-15 | Bozic Carmen | S-Sale | 1,354.00 | $453.45 | $613,971 |
| 2026-05-12 | Bozic Carmen | S-Sale | 6,988.00 | $450.00 | $3.1M |
| 2026-05-01 | Upadhyay Suketu | A-Award | 796.00 | $0.00 | $0 |
| 2026-05-01 | Upadhyay Suketu | A-Award | 2,866.00 | $424.45 | $1.2M |
| 2026-05-01 | Upadhyay Suketu | D-Return | 796.00 | $0.00 | $0 |
| 2026-05-01 | Thornberry Nancy | A-Award | 472.00 | $0.00 | $0 |
| 2026-05-01 | Thornberry Nancy | D-Return | 398.00 | $0.00 | $0 |
| 2026-05-01 | Thornberry Nancy | A-Award | 1,433.00 | $424.45 | $608,237 |
| 2026-05-01 | Thornberry Nancy | A-Award | 398.00 | $0.00 | $0 |
| 2026-05-01 | Schneider Jennifer | A-Award | 472.00 | $0.00 | $0 |
| 2026-05-01 | Schneider Jennifer | A-Award | 1,433.00 | $424.45 | $608,237 |
| 2026-05-01 | Schneider Jennifer | D-Return | 796.00 | $0.00 | $0 |
| 2026-05-01 | Schneider Jennifer | A-Award | 796.00 | $0.00 | $0 |
| 2026-05-01 | SACHS BRUCE I | A-Award | 2,866.00 | $424.45 | $1.2M |
| 2026-05-01 | MCKENZIE DIANA | A-Award | 796.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VRTX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for VRTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30